MorphoSys AG Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
11/9/2009 11:12:12 AM
More...
|
MorphoSys AG Reports Results for the First Nine Months of 2009
10/28/2009 12:17:18 PM
More...
|
MorphoSys AG to Host Q3 2009 Conference Call on October 28, 2009
10/22/2009 10:14:47 AM
More...
|
MorphoSys AG and Daiichi Sankyo Co Ltd. Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
10/20/2009 7:18:06 AM
More...
|
MorphoSys AG Appoints Lisa Rojkjaer, MD Head of Clinical Development
9/16/2009 11:27:43 AM
More...
|
MorphoSys AG Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
9/8/2009 2:32:09 PM
More...
|
MorphoSys AG to Present at Six Upcoming Investor Conferences
8/28/2009 9:07:37 AM
More...
|
MorphoSys AG Reports Six Months 2009 Results
7/29/2009 11:27:58 AM
More...
|
MorphoSys AG to Host Q2 2009 Conference Call on July 29, 2009
7/23/2009 10:42:44 AM
More...
|
MorphoSys AG: AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used in Clinical Diagnostic Kits
7/9/2009 6:54:47 AM
More...
|
|